White blood cells (WBC) > 3 x 10^9/L, within 28 days prior to administration of study treatment
White blood cells (WBC) > 3 x 10^9/L, measured within 28 days prior to administration of study treatment
White blood cells (WBC) >= 3,000 cells/uL (3.0 x 10^9 L) or
Measured within 28 days prior to registration: white blood cells > 3,000/mcL
More than 5% white blood cells in bone marrow.
White blood cells (WBC) > 15,000 cells/mcL (15 cells x 10^9/L) at screening. In subjects with WBC > 15,000 cells/mcL at screening with lymphocyte predominance, subject may be deemed eligible for the trial by the Amgen physician, after discussion with the investigator.
White blood cells (WBC) >= 3.0 x 10^9/L
White blood cells (WBC) > 3 x 10^9/L
White blood cells (WBC) < 4,000
White blood cells (WBC) >= 3 x 10^9/L, completed within 14 days prior to the date of registration
White blood cells >= 3,000/microliter
White blood cells (WBC) > 15,000 cells/mcL at screening
White blood cells (WBC) >= 2.5
White blood cells (WBC) > 2,500/mcL
Within 7 days prior to administration of study treatment: White blood cells (WBC) > 3 x 10^9/L.
White blood cell (WBC) >= 3 x 10^9 cells/mL
White blood cells (WBC) > 3 x 10^9/L
White blood cells (WBC) >= 3 x 10^9 cells/mL
White blood cells (WBC) >= 3,000/mcL
Circulating white blood cells < 25.1000000000 /L (with or without use of hydroxycarbamide).
White blood cells (WBC) =< 10 x 10^9/L
White blood cells (WBC) >= 2,000/mcL
White blood cells (WBC) >= 3.0 x 10^9/L
White blood cells (WBC) >= 3 x 10^9 cells/ml
White blood cells (WBC) >= 3,000/mcL
White blood cells (WBC) < 200/mcl
White blood cells (WBC) > 3x10^9/L (measured within 28 days prior to administration of study treatment)
White blood cells (WBC) > 3.0
White blood cells (WBC) < 3.5 K/mcL
White blood cells (WBC) >= 3.0 x 10^9/L
Patients must have lymphocytosis with white blood cells between 30,000-100,000/uL in order to collect adequate leukemia cells for vaccine production
White blood cells (WBC) >= 3.0
White blood cells (WBC) >= 3.0
White blood cells (WBC) >= 3,000/mcL
White blood cells (WBC) >= 2,000/mcL
White blood cells (WBC) > 3000/mcL
DONOR: White blood cells (WBC), platelet count near normal limits (± 10%)
White blood cells (WBC) > 3 x 10^9/L, measured within 28 days prior to administration of study treatment
White blood cells (WBC) of 3000 per mcL
White blood cells (WBCs) >= 2000 cells/uL
White blood cells (WBC) >= 3.0 x 10^9/L
White blood cells (WBC) > 3,000/mcL
White blood cell count (WBC) >= 3,000 cells/mcL
White blood cells (WBCs) >= 2000 cells u/L
White blood cells (WBC) >= 3,500/mcL
White blood cells (WBC) > 3.0 ml
White blood cells (WBC) >= 2500 cells/ul
White blood cells (WBC) >= 3.0 x 10^9 cells/L
White blood cells (WBC) < 2.0
Patients receiving hydroxyurea may continue receiving it for up to 14 days after the start of protocol treatment if white blood cells (WBC) > 30 x10^9/L
Lymphocytes < 15% of total white blood cells (WBCs) at baseline
White Blood Cells (WBC) ? 3.0x10E9/L including
White blood cells ? 2000/µL
White blood cells (WBC) >= 2.0
White blood cells greater than 1.5 x 10^3/ul (or 1,500 cells/mm^3); these results can be within last 60 days from the day of signing informed consent
WBC count ? 3.0 x 103 cells/µL
White blood cells (WBC) < 3.5/ml
White blood cells (WBC) >= 3,000/mL
White blood cells (WBC) < 4,000
White blood cells >= 2,000/mcL
White blood cells (WBC) >= 3 x 10^9/L, transfusions and growth factors are allowed
Total white blood cells (WBC) >= 4.0 x 10^3/mcL within 28 days prior to registration
White blood cells >= 3,000/microliter
White blood cells (WBC) within institutional limits of normal or judged to be not clinically significant by the investigator
Peripheral blood white blood cells (WBC) greater than 2,000 per microliter (required for collection of dendritic cell precursors)
White blood cells (WBC) > 1500 cells/uL
